Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed Medicare Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

CED lives: "I would like to stop the rumor that CED is dead," said Steve Phurrough, MD, director of CMS' Coverage & Analysis Group May 3 at AdvaMed's Medicare policy meeting in Baltimore. "We've had some issues develop" with the draft policy for coverage-with-evidence-development, in particular with the Office for Human Research Protections and patient privacy regulations, he said. Such issues led to "false starts" in the National Oncologic PET registry, which under a January 2005 national coverage decision requires patients to enroll in a registry so they can get certain cancer-monitoring scans (1"The Gray Sheet" March 20, 2006, p. 9). But most issues have been resolved over the last several months, said Phurrough, and the PET registry is scheduled to open May 8. CMS plans to release a second draft guidance document to address and ask for comments on those concerns in the near future...

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts